This report has been identified as b.Braun medical, inc.Internal report (b)(4).The actual device involved in the reported incident was not returned for evaluation.R&d investigation show that the logs are incomplete.Both folders in b.Docs have the same log files, which only go until 11:40am on jan24th, and do not show any compounded orders or even any dispenses at all.The issue was reported that "at the end of production that day when the final patient order had completed, the staff noticed what appeared to be residue left over from the lipids hung that day" since there are no compounded orders, there is nothing close to the time that they were concerned about residual lipids.All that can be seen is that they pass leak check on the first attempt, and what their template initially was (though they might have modified it by the time the issue occurred) with the knowledge that the sequence might have changed, and without knowing the details of the order that may have caused issues, some notes on the default template sequence: 1) there is no indication that the template is not ideal for lipid residue.Lipid is not pumping last, swfi comes after it.2) if there was concern about the visible residue being ca/phos interaction instead of lipid, they have a ui buffer on kphos and naphos to begin the day.This means that there should be adequate separation of ca/phos to minimize any possible interaction.Again, these buffers could have been removed later in the day.At this point (4/11/2022) , if the logs haven't been gathered or retained by vanderbilt, the system would have cleared them because the panel only stores the last 60 days of software logs.
|